 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 04, 2020 GLOBE NEWSWIRE -- Applied Genetic Technologies Corporation Nasdaq: AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus AAV-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President Chief Executive Officer, will present at the Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 11, 2020 at 10:20 am ET.A live audio webcast of the presentation will be available by visiting A replay will be available on the Companys website following the event.About AGTC AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system CNS diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. Initially focusing on ophthalmology, we are leveraging our best-in-class investigational technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia ACHM CNGB3 ACHM CNGA3. Our pre-clinical programs build on our industry leading AAV manufacturing technology and expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.IRPR CONTACTS: David Carey IR or Glenn Silver PR Lazar FINN Partners T: 212 867-1768 or 646 871-8485 or Contact: Bill Sullivan Chief Financial Officer Applied Genetic Technologies Corporation T: 617 843-5728 Potter Chief Business Officer Applied Genetic Technologies Corporation T: 617 413-2754 